{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T13:47:58Z","timestamp":1766065678037,"version":"build-2065373602"},"reference-count":7,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1016\/j.jaad.2005.11.1064","type":"journal-article","created":{"date-parts":[[2006,3,18]],"date-time":"2006-03-18T07:36:31Z","timestamp":1142667391000},"page":"742-743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Alefacept treatment of psoriatic nail disease: How severe should nail psoriasis be?"],"prefix":"10.1016","volume":"54","author":[{"given":"John E.M.","family":"K\u00f6rver","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.M.","family":"van de Kerkhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel C.","family":"Pasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2005.11.1064_bib1","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jaad.2005.01.101","article-title":"Alefacept in the treatment of psoriatic nail disease: a small case series","volume":"52","author":"Cassetty","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2005.11.1064_bib2","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000246274","article-title":"Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients","volume":"193","author":"de Jong","year":"1996","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2005.11.1064_bib3","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/120347540400800208","article-title":"Nail psoriasis: combined therapy with systemic cyclosporin and topical calcipotriol","volume":"8","author":"Feliciani","year":"2004","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaad.2005.11.1064_bib4","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.1365-2230.2000.00663.x","article-title":"Management of nail psoriasis","volume":"25","author":"de Berker","year":"2000","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2005.11.1064_bib5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0190-9622(95)90189-2","article-title":"Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement","volume":"32","author":"Mahrle","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2005.11.1064_bib6","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1067\/S0190-9622(03)00910-1","article-title":"Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis","volume":"49","author":"Rich","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2005.11.1064_bib7","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2004.09.012","article-title":"Remission and time of resolution of nail psoriasis during infliximab therapy","volume":"52","author":"Bianchi","year":"2005","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962205045974?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962205045974?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:02:58Z","timestamp":1759269778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962205045974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S0190962205045974"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2005.11.1064","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2006,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alefacept treatment of psoriatic nail disease: How severe should nail psoriasis be?","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2005.11.1064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}